2.2 针对EGFR突变NSCLC治疗的联合用药策略EGFR突变是我国最为常见的NSCLC驱动基因变异, 目前酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)耐药是EGFR抑制剂的治疗难点。相较于EGFR突变型, SHP2对EGFR野生型下游ERK磷酸化的促进作用要更加显著[41...
SHP2变构抑制剂的研究进展 堵桐弘，吕遐师，赖宜生* 中国药科大学新药研究中心，天然药物活性组分与药效国家重点实验室，江苏省代谢性疾病药物重点实验室，江苏 南京 收稿日期：2022年4月29日；录用日期：2022年5月11日；发布日期：2022年5月31日 摘 要 蛋白酪氨酸磷酸酶在维持蛋白质酪氨酸磷酸化的稳态中起...
2. The SHP2 Inhibitor RMC-4630 in Patients with KRAS-mutant Non-Small Cell Lung Cancer:Preliminary Evaluation of a First-in-man Phase 1 Clinical Trial, https://revmed.egnyte.com/dl/vkK5A3sCWn/Plenary1_The_SHP2_inhib...
2. The SHP2 Inhibitor RMC-4630 in Patients with KRAS-mutant Non-Small Cell Lung Cancer:Preliminary Evaluation of a First-in-man Phase 1 Clinical Trial,https://revmed.egnyte.com/dl/vkK5A3sCWn/Plenary1_The_SHP2_inhibitor_RMC-4630_in_patients_with_KRAS-mutant_non-small_cell_lung_cancer_-...
Second SHP2 inhibitor approved by the US FDA to enter clinical development FDA's orphan drug designation received for esophageal cancer (including esophageal squamous cell carcinoma) Summary Jacobio independently developed the SHP2 inhibitors, JAB-3312 , using a drug design platform exploiting the allos...
加科思在北京、上海和波士顿设有研发中心,拥有诱导异位药物研发平台(IADDP)和 iADC 平台。 网址:https://en.prnasia.com/releases/global/jacobio-announces-china-cde-clearance-for-phase-iii-clinical-trial-of-shp2-inhibitor-plus-kras-g12c-inhibitor-436901.shtml...
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial. Sai-Hong Ignatius Ou, University of California Irvine, Irvine, CA, USA SHP2是由PTPN11基因编码的非受体蛋白酪氨酸磷酸酶,负责催化磷酸酪氨酸的去...
Navire Pharma Inc., a BridgeBio company, has initiated Phase 1 clinical trials to evaluate the safety, tolerability, and preliminary efficacy of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors. We understand that some patients may wish to access our investigational drug that ha...
A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trialdoi:10.1016/j.jtho.2019.12.041S.I. OuM. KoczywasS. UlahannanP. JanneJ. Pacheco...
In PAH rat, curatively treated with Shp2 inhibitor Phps-1markedly decreased MCT-induced elevation in mPAP (Fig. 1a) as well as RVSP (Fig. 1b). However, the Phps-1 had not significant effect on SAP (Fig. 1c). Similarly, Phps-1 partially reversed MCT induced increase of RVH, as ...